Phil Vickers Phil Vickers started last week as president and CEO of Solu Therapeutics, a Longwood Fund startup developing small molecule-antibody chimeras.
He takes the place of Longwood executive partner David Donabedian, who has taken the early CEO roles at a…
Click here to view original post
